GlobalData on MSN8d
FDA grants orphan drug status to Arbor Biotechnologies’ PH1The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...
Arbor Biotechnologies Inc.’s ABO-101 has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of primary hyperoxaluria type 1 (PH1).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback